Lantheus Holdings competitors, on the record

Who Lantheus Holdings names

In its own words

1. Blue Earth Diagnostics Ltd., Telix Pharmaceuticals Limited

   Word for word“• For PYLARIFY, our principal competitors are currently Telix Pharmaceuticals Limited, Blue Earth Diagnostics Ltd., a subsidiary of Bracco and Novartis AG, as well as other non-PSMA PET imaging agents; and there is the potential for future competition from others who may submit regulatory applications in anticipation of PYLARIFY’s NCE exclusivity expiry in May 2026.” 10-K for 2025

2. Bracco Diagnostics Inc.

   Word for word“DEFINITY currently competes with ultrasound enhancing agents produced by GE HealthCare Limited (“GE Healthcare”) and Bracco Diagnostics Inc. (“Bracco”), as well as echocardiography without ultrasound enhancing agents and other non-echocardiography agents, and there is the potential for future competition from generic manufacturers who may submit regulatory applications using DEFINITY as the reference listed drug (RLD).” 10-K for 2025

3. Curium, Novartis AG

   Word for word“For LNTH-2501, our principal competitors may include Curium and Novartis AG.” 10-K for 2025

4. Eli Lilly and Co

   Word for word“Neuraceq currently competes with two commercially available F-18 beta-amyloid-targeting PET imaging agents from Eli Lilly and Co (“Lilly”) and GE Healthcare.” 10-K for 2025

5. GE Healthcare

   Word for word“• For Neuraceq, our competitors currently include Lilly and GE Healthcare.” 10-K for 2025

6. ITM Radiopharma, RayzeBio

   Word for word“For example, for PNT2003, our principal competitors may include Novartis AG; ITM Radiopharma; Curium, and RayzeBio (acquired by Bristol Myers Squibb).” 10-K for 2025

Read from Lantheus Holdings’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.